These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1782072)

  • 21. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
    Schilling T; Pecherstorfer M; Blind E; Leidig G; Ziegler R; Raue F
    J Clin Endocrinol Metab; 1993 Mar; 76(3):801-3. PubMed ID: 8445039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
    Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
    J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
    Tal A; Graves L
    South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.
    Heatley S
    Int J Palliat Nurs; 2001 Jun; 7(6):301-2, 304-7. PubMed ID: 12066026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accumulation of carboxy-terminal fragments of parathyroid hormone-related protein in renal failure.
    Orloff JJ; Soifer NE; Fodero JP; Dann P; Burtis WJ
    Kidney Int; 1993 Jun; 43(6):1371-6. PubMed ID: 8315952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
    Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT
    Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S; Tisell LE; Lindstedt G; Lundberg PA
    Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bone metastases: pathogenesis and treatment with diphosphonates].
    Body JJ
    Bull Mem Acad R Med Belg; 1997; 152(3):169-74; discussion 174-6. PubMed ID: 9491638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
    Gurney H; Kefford R; Stuart-Harris R
    Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypercalcemia and bone metastases in breast cancer.
    Warrell RP
    Curr Opin Oncol; 1990 Dec; 2(6):1097-103. PubMed ID: 2151596
    [No Abstract]   [Full Text] [Related]  

  • 32. Rat model of the hypercalcaemia induced by parathyroid hormone-related protein: characteristics of three bisphosphonates.
    Komatsu Y; Imai Y; Itoh F; Kojima M; Isaji M; Shibata N
    Eur J Pharmacol; 2005 Jan; 507(1-3):317-24. PubMed ID: 15659323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population.
    Lee JK; Chuang MJ; Lu CC; Hao LJ; Yang CY; Han TM; Lam HC
    J Endocrinol Invest; 1997; 20(7):404-9. PubMed ID: 9309539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pamidronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors.
    Yaghoobian J; Morieux C; Denne MA; Bouizar Z; Ureña P; de Vernejoul MC
    Horm Metab Res; 1998 May; 30(5):249-55. PubMed ID: 9660083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary excretion of parathyroid hormone-related protein fragments in patients with humoral hypercalcemia of malignancy and hypercalcemic tumor-bearing nude mice.
    Imamura H; Sato K; Shizume K; Satoh T; Kasono K; Ozawa M; Ohmura E; Tsushima T; Demura H
    J Bone Miner Res; 1991 Jan; 6(1):77-84. PubMed ID: 2048434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intractable hypercalcaemia due to parathyroid hormone-related peptide secretion by a carcinoid tumour.
    Mantzoros CS; Suva LJ; Moses AC; Spark R
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):373-5. PubMed ID: 9156050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypercalcaemia of melanoma: incidence, pathogenesis and therapy with bisphosphonates.
    des Grottes JM; Dumon JC; Body JJ
    Melanoma Res; 2001 Oct; 11(5):477-82. PubMed ID: 11595884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
    Gallacher SJ; Fraser WD; Logue FC; Dryburgh FJ; Cowan RA; Boyle IT; Ralston SH
    Calcif Tissue Int; 1992 Dec; 51(6):419-23. PubMed ID: 1333351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
    Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic effects of pamidronate in patients with metastatic bone disease.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    Br J Cancer; 1996 May; 73(9):1089-95. PubMed ID: 8624269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.